Santori & Peters Inc. purchased a new stake in Pfizer (NYSE:PFE) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 30,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,031,000. Pfizer comprises approximately 0.9% of Santori & Peters Inc.’s portfolio, making the stock its 14th biggest holding.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of Pfizer by 2.8% during the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after buying an additional 12,183,218 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Pfizer by 11.9% during the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after buying an additional 7,534,957 shares during the last quarter. Stifel Financial Corp lifted its stake in shares of Pfizer by 5,413.5% during the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock worth $262,515,000 after buying an additional 7,226,697 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Pfizer by 46.6% during the 4th quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company’s stock worth $816,395,000 after buying an additional 7,161,892 shares during the last quarter. Finally, Boston Partners lifted its stake in shares of Pfizer by 18.4% during the 3rd quarter. Boston Partners now owns 27,741,320 shares of the biopharmaceutical company’s stock worth $990,365,000 after buying an additional 4,314,466 shares during the last quarter. Hedge funds and other institutional investors own 71.65% of the company’s stock.

PFE has been the subject of several analyst reports. SunTrust Banks reiterated a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. Morningstar set a $38.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Finally, Bank of America set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $40.08.

Pfizer opened at $35.71 on Friday, Marketbeat Ratings reports. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer has a 12 month low of $35.64 and a 12 month high of $35.80. The stock has a market capitalization of $212.46 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 1.77 and a beta of 0.89.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period last year, the firm earned $0.69 EPS. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. equities research analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.

In related news, insider Charles H. Hill sold 42,393 shares of Pfizer stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Douglas M. Lankler sold 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total transaction of $1,844,500.00. Following the sale, the insider now directly owns 133,057 shares in the company, valued at $4,908,472.73. The disclosure for this sale can be found here. Insiders have sold a total of 380,349 shares of company stock worth $13,829,340 over the last ninety days. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.